Loading...
•
Dec 31, 2021
AcelRx Q4 2021 Earnings Report
AcelRx reported fourth quarter and full year 2021 financial results, highlighting DSUVIA unit sales growth and strategic portfolio expansion with Niyad™ (nafamostat).
Key Takeaways
AcelRx Pharmaceuticals reported its Q4 and full year 2021 financial results, with a focus on expanding its product portfolio and adapting to the evolving healthcare environment. DSUVIA unit sales saw significant growth in Q4, although net revenues were minimal due to a reserve for potential returns. The company is also advancing the development of Niyad™ and pre-filled syringe product candidates.
DSUVIA unit sales increased by 142% in Q4 2021 compared to Q3 2021.
AcelRx had $51.6 million in cash and short-term investments as of December 31, 2021.
AcelRx expanded its late-stage pipeline with Niyad™ (nafamostat), which received Breakthrough Designation status from the FDA and an ICD-10 procedural code from CMS.
The company is focusing on the development and approval of pre-filled syringes and Niyad (nafamostat) product candidates.
Forward Guidance
AcelRx provided 2022 year-end goals including NDA submissions for pre-filled syringe product candidates, the manufacturing of initial lots of nafamostat, and quarterly combined R&D and SG&A expense.
Positive Outlook
- Submission of two NDAs for pre-filled syringe product candidates.
- Manufacturing of initial lots of nafamostat.
- Quarterly combined R&D and SG&A expense is expected to be approximately $9-$10 million.
- Annual debt service is expected to approximate $10 million.
- Annual capital expenditures are expected to approximate $2 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...